Ticlopidine (Ticlid)

Subscribe to Selected New Research on Ticlopidine

888 relevant articles (93 outcomes, 123 trials/studies) found for this Drug

Description: Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.

Also Known As:

Ticlid; 53-32C; Ticlodix; Ticlodone; Ticlopidine Hydrochloride; 53 32C; 5332C; Hydrochloride, Ticlopidine; Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Experts

1.	Uchiyama, Shinichiro: 2 articles (01/2008 - 09/2003)
2.	Yagi, H: 2 articles (03/2002 - 10/2001)
3.	Fujimura, Y: 2 articles (03/2002 - 10/2001)
4.	Matsumoto, M: 2 articles (03/2002 - 10/2001)
5.	Ishizashi, H: 2 articles (03/2002 - 10/2001)
6.	Szot, Paweł: 1 article (07/2008)
7.	Kasper, Marta: 1 article (07/2008)
8.	Brzostek, Tomasz: 1 article (07/2008)
9.	Rzeszutko, Marcin: 1 article (07/2008)
10.	Kowalski, Robert: 1 article (07/2008)

Related Diseases

1.	Stroke (Strokes) 03/01/1996 - "Thus, ticlopidine is effective in reducing the risk of recurrent cerebral ischaemia and stroke" 10/01/1993 - "Ticlopidine may also be effective in reducing the risk of recurrent stroke in patients who have had a completed thromboembolic stroke." 10/01/1993 - "Two large, multicenter trials have shown that ticlopidine is effective in reducing the risk of fatal and nonfatal stroke in both men and women" 06/01/1992 - "CONCLUSIONS: Ticlopidine is effective for both primary and secondary stroke prevention" 09/01/1991 - "In contrast, major stroke prevention trials using ticlopidine have demonstrated equal benefit in women and in men" Order ALL the reference details at left...
2.	Thrombosis (Thrombus) 03/01/1993 - "Since shear-induced platelet aggregation can cause thrombotic occlusions in stenotic arterial vessels, our findings may explain the therapeutic efficacy of ticlopidine in arterial thrombosis." 01/01/1983 - "Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications." 01/01/2006 - "In j-Cypher trial, a observational registry trial in Japan, revealed that the subacute thrombosis rate was lower level of the other studies and safety of DES utilization with ticlopidine based antiplatelet regimen" 05/01/2007 - "These late thromboses occurred about 2 years after SES implantation and over 1.5 years after discontinuation of ticlopidine." 04/14/2006 - "These findings thus support the overall safety and effectiveness of ticlopidine after DES implantation, and also confirm the increased risk of late thrombosis when premature withdrawal of thienopyridines occurs." Order ALL the reference details at left...
3.	Myocardial Infarction 04/01/2003 - "A 52-year-old man with acute myocardial infarction developed respiratory distress 2 days after receiving ticlopidine for coronary artery stenting" 10/01/1999 - "A 54-year-old man had been treated with Ticlopidine for antithrombotic therapy after a myocardial infarction" 11/01/1998 - "The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions." 01/01/1997 - "No ischemic insult, myocardial infarction, death due to cardiovascular pathology was observed in 138 patients, to whom after the operation on the arteries of truncus brachiocephalicus the ticlid was administered" 12/01/1991 - "Nevertheless, this report strongly suggests that such patients can benefit from antiplatelet treatment with ticlopidine; the benefit mainly depends on the protective effect against myocardial infarction." Order ALL the reference details at left...
4.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 11/01/2000 - "In peripheral arterial disease, the Swedish Ticlopidine Multicentre Study (STIMS) showed that ticlopidine was very effective against placebo" 07/01/2002 - "Ticlopidine, an inhibitor of platelet aggregation, is widely used for peripheral arterial disease" 07/11/1996 - "Here, we report for the first time that in patients with peripheral arterial disease and in cats with extracorporal circulation ticlopidine evokes instantaneous thrombolytic or fibrinolytic effects which are not associated with inhibition of platelet aggregation" 01/01/1994 - "Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease." 08/01/1993 - "The findings suggest that ticlopidine can improve the cutaneous microcirculation in patients with peripheral vascular disease." Order ALL the reference details at left...
5.	Neutropenia 06/01/1997 - "Despite the potential benefits of therapy with ticlopidine observed in these studies, hematologic monitoring is required to detect neutropenia that may occur during ticlopidine therapy" 07/01/2002 - "Severe neutropenia induced by ticlopidine" 07/01/2001 - "The patient evolved with neutropenia induced by ticlopidine after 10 days of treatment" 07/01/2000 - "Only ticlopidine increased the odds of neutropenia" 05/11/1999 - "Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	clopidogrel (Plavix)
3.	Dipyridamole (Persantine)
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	Heparin (Liquaemin)
6.	cilostazol (Pletal)
7.	Warfarin (Coumadin)
8.	Ticlopidine (Ticlid)
9.	triflusal
10.	abciximab (ReoPro)

Related Therapies and Procedures

1.	Stents
2.	Angioplasty (Angioplasties)
3.	Transplants (Transplant)
4.	Renal Dialysis (Hemodialysis)
5.	Lasers (Laser)

Best Treatments:
Research Summary Report
on Stroke

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2086 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>